Pregabalin
Product Images NDC 76420-659

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 76420-659). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Asclemed Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Graph1 (Graph1)

Line graph depicting the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at 200 mg, 100 mg, and 25 mg three times a day compared to placebo. The x-axis shows percent improvement in pain, and the y-axis shows the percent of patients improved, with curves for each dosing group and placebo displayed.*

FDA Label Image

Graph10 (Graph10)

A line chart comparing the percent of subjects improved from baseline to Week 12 on the BOCF scale between Pregabalin and placebo groups. The y-axis shows percent of subjects improved, and the x-axis shows percent improved from baseline to Week 12, with Pregabalin represented by a solid line and placebo by a dashed line.*

FDA Label Image

Graph11 (Graph11)

A chart showing the percent of subjects improved over a range of percent improvement from baseline to week 16, comparing Pregabalin and placebo groups. The x-axis represents percent improvement, and the y-axis shows the percent of subjects improved. The graph includes a solid line for Pregabalin and a dashed line for placebo, illustrating higher improvement percentages for Pregabalin across the scale.*

FDA Label Image

Graph2 (Graph2)

A line graph comparing percent improvement in pain from baseline between Pregabalin 100 mg three times a day and placebo. The x-axis shows percent improvement in pain, ranging from 0 to 100%, while the y-axis shows the percent of patients improved, up to 100%. Two lines illustrate patient response rates for Pregabalin and placebo groups.*

FDA Label Image

Graph3 (Graph3)

A line graph depicting the percent of patients improved relative to the percent improvement in pain from baseline. It compares groups receiving Pregabalin at doses of 75 mg, 150 mg, and 300 mg twice daily, versus a placebo group. The graph shows decreasing percentages of patients improved as pain improvement thresholds increase.*

FDA Label Image

Graph4 (Graph4)

Chart showing the percent of patients improved versus percent improvement in pain from baseline among three groups: patients taking Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph compares pain improvement outcomes across these treatment groups.*

FDA Label Image

Graph5 (Graph5)

A line graph showing the percent improvement in pain from baseline against the percent of patients improved for Pregabalin 100mg three times a day, Pregabalin 50mg three times a day, and placebo. The graph illustrates treatment effectiveness comparisons among the three groups over a range of pain improvement percentages.*

FDA Label Image

Graph6 (Graph6)

A bar chart comparing responder rates (%) across different dosing regimens of pregabalin in two studies (E1 and E3). The x-axis lists dosages with placebo controls, and the y-axis shows responder rates from 0% to 60%. Bars indicate increased responder rates with higher pregabalin doses versus placebo in each study.*

FDA Label Image

Graph7 (Graph7)

A line graph depicting seizure reduction as a median percentage change from baseline against pregabalin doses in mg/day. The graph includes data points for four studies labeled E1 BID, E2 TID, E3 BID, and E3 TID, with significance levels (p-values) indicated for comparisons versus placebo dose 0 mg/day.*

FDA Label Image

Graph8 (Graph8)

A Kaplan-Meier type plot depicting the percent of patients improved versus percent improvement in pain from baseline, comparing daily doses of Pregabalin (600 mg, 450 mg, 300 mg) and placebo. The graph indicates the relationship between different Pregabalin doses and pain improvement over a range of 0-100%.*

FDA Label Image

Graph9 (Graph9)

A Kaplan-Meier survival curve comparing Pregabalin and placebo over 180 days. The y-axis shows the estimated percentage of subjects without a specific event, and the x-axis shows time in days. The solid line represents Pregabalin, and the dashed line represents placebo, illustrating differences in subject outcomes over time.*

FDA Label Image

Formula (Formula)

An illustration showing the formula for calculating creatinine clearance (CLCr). The formula involves age in years, weight in kilograms, serum creatinine in mg/dL, and includes a multiplication factor of 0.85 for female patients.*

FDA Label Image

Pregabalin-25-90s (Pregabalin 100)

Labels for Pregabalin Capsules 100mg by Enovachem Pharmaceuticals, showing package sizes of 30, 60, and 90 capsules. The labels include NDC numbers 76420-583-30, 76420-583-60, and 76420-583-90, with information on packaging, manufacturing for Apotex Inc., capsule description as light orange and opaque, and regulatory warnings about prescription dispensing and storage conditions.*

FDA Label Image

Pregabalin Structure (Pregabalin Structure)

Chemical structure of Pregabalin showing its molecular configuration including an amino group, a carboxyl group, and a branched hydrocarbon chain.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.